• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

3-month disability progression reduced with fingolimod

April 13, 2011  

B cell drug set to enter phase III testing

March 30, 2011  

Dalfampridine may improve walking ability: phase III results

March 9, 2011  

Vitamin D and UV exposure during pregnancy/postpartum period

January 26, 2011  

EDSS may underrepresent progression

January 12, 2011  

Demyelination reported following HPV vaccination

October 18, 2010  

Need for early, aggressive treatment in RRMS

October 18, 2010  

New data on fingolimod in RRMS

October 18, 2010  

Treatment discontinuations common in CIS

October 15, 2010  

Switching to fingolimod: TRANSFORMS extension study results

October 15, 2010  
Previous
38
39
40
41
42
Next

Browse by Topic

  • MSToronto2026 (1)
  • MS (445)
  • CLINICAL CASES (22)
  • EAN 2026 (2)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS posted on September 17, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions